DNA sequence-dependent fluorescence of doxorubicin for turn-on detection of biothiols in human serum

Recent advances in ZnO nanostructure-based electrochemical sensors and biosensors

Nanostructured metal oxides, such as zinc oxide (ZnO), are considered as excellent materials for the fabrication of highly sensitive and selective electrochemical sensors and biosensors due to their good properties, including a high specific surface area, high catalytic efficiency, strong adsorption ability, high isoelectric point (IEP, 9.5), wide band gap (3.2 eV), biocompatibility and high electron communication features. Thus, ZnO nanostructures are widely used to fabricate efficient electrochemical sensors and biosensors for the detection of various analytes. In this review, we have discussed the synthesis of ZnO nanostructures and the advances in various ZnO nanostructure-based electrochemical sensors and biosensors for medical diagnosis, pharmaceutical analysis, food safety, and environmental pollution monitoring.

Enhanced growth inhibition of prostate cancer in vitro and in vivo by a recombinant adenovirus-mediated dual-aptamer modified drug delivery system

The peptide aptamer DUP-1 targets prostate-specific membrane antigen (PSMA)-negative cells, while the RNA aptamer A10-3.2 targets PSMA-positive prostate cancer cells. Moreover, the tumor-suppressor gene phosphatase and tensin homolog (PTEN) and the chemotherapeutic agent doxorubicin (DOX) effectively inhibit prostate cancer, and a recombinant adenovirus (Ad5) mediates high gene transfer efficiency. Here, we design a dual-aptamer modified tumor targeting gene and DOX delivery system mediated by recombinant adenovirus (A10-3.2(DOX)/DUP-1-PEG-Ad5, ADDP-Ad5). DUP-1 and A10-3.2 are connected to the adenovirus through polyethylene glycol (PEG), PTEN is integrated into Ad5, and DOX is embedded into the double chain of aptamer A10-3.2. The PEG-modification rate of Ad5 is 98.70 ± 2.43%. The DUP-1 and A10-3.2 modified products yield 80.40 ± 1.36% and 82.20 ± 2.14%, respectively. The uptake of ADDP-Ad5 and the expression of the reporter gene are enhanced by the system in PSMA-positive LNCaP and PSMA-negative PC3 human prostate cancer cells. ADDP-Ad5 significantly inhibits the cell growth of both LNCaP and PC3 cells. More importantly, ADDP-Ad5 is active in vivo against LNCaP and PC3 tumor xenografts and exhibits no significant toxicity to the mice. Therefore, ADDP-Ad5 may have clinical potential in prostate cancer therapy.

Label-free DNA-based biosensors using structure-selective light-up dyes

Label-free biosensors (LFBs) have demonstrated great potential in cost-effective applications. This review collected the latest reported works which employed structure-selective nucleic acid dyes for the development of DNA-based LFBs.